NuPathe — Investor Presentation (September 2013)
32 slides from NuPathe's investor presentation, Sep 11, 2013
Slide 1: Corporate Presentation
Corporate Presentation September 11, 2013 © 2013 NuPathe Inc. All rights reserved.
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All remarks and information that are not historical facts are hereby identified as forward-looking statements for this purpose and include,
Slide 3: NuPathe: A Specialty CNS Pharmaceutical Company
3 • ZECUITY® – the first and only FDA-approved migraine patch •31 million migraine sufferers in the U.S. •Significant unmet need – migraine-related nausea (MRN) •Focused on key objectives •Preparing for 4Q13 launch •Securing commercial partners for ZECUITY •Two early-stage CNS drug candidates •Schiz
Slide 4: ZECUITY - First and Only FDA Approved Migraine Patch
4 •Game-changing disruptive technology for migraine .Delivers sumatriptan, the #1 prescribed migraine medication .Five Orange-Book listed patents provide protection to April 2029 •Uniquely positioned to address migraine headache pain and MRN .Rapid relief of both headache pain and MRN with a low rat
Slide 5: ZECUITY: Game-Changing, Disruptive Technology
5 •Intelligent, active transdermal delivery .Microprocessor supports highly controlled and consistent delivery •Multiple safety checks within seconds of activation •Continuous monitors skin resistance and adjusts drug delivery •Delivers 6.5 mg of sumatriptan with minimal patient-to-patient variabili
Slide 6: ZECUITY: First and Only Migraine Patch
6 Easy to use, single-use, disposable •Applied to upper arm or thigh during a migraine •Bypasses GI tract •Rapidly delivers sumatriptan ZECUITY: First and Only Migraine Patch
Slide 7: MRN is a Prominent Component of Migraine Disease Burden
7 MRN is a Prominent Component of Migraine Disease Burden 31M 16M 8M 0 5 10 15 20 25 30 35 Adult Migraine Sufferers Diagnosed & Treated MRN in Majority of Attacks U.S. Adults (millions) Core Zecuity Target Patients •Affects females to males 3:13 •Disease of the working class population, 20 – 50 year
Slide 8: Large Market Opportunity with Significant Unmet Disease Burden
8 Large Market Opportunity with Significant Unmet Disease Burden •~8 million patients experience MRN in a majority of their attacks1,2,3 •Patients with MRN at time of treatment are less likely to respond to oral triptans4,5 •Migraineurs with frequent MRN drive higher direct medical costs than patien
Slide 9: Current Options Often Fail Patients with MRN
9 •Triptan tablets/melts .Patients delay/avoid orals – too nauseated/fear of vomiting1,2,3 .Gastroparesis can impact absorption and response to oral triptans4 •Triptan nasal sprays and injections •Result: Patients frequently switch7 .80% have tried at least two triptans .50% have tried three or more
Slide 10: ZECUITY is the Solution
10 ZECUITY is tailored for migraine patients who suffer from MRN ZECUITY is the Solution
Slide 11: Excellent Efficacy and Safety Demonstrated through Robust Clinical Program
11 •Extensive clinical program including more than 800 patients and 10,000 patch applications •Pivotal Phase 3 study (n=530) published in Headache, Oct 2012 •Two 12-month, repeat use, open-label trials (n=662) .NP101-008 published in Headache, April 2012 Excellent Efficacy and Safety Demonstrated th
Slide 12: Pivotal Phase 3 Data Published in HEADACHE Oct 2012
12 •Pain relief and nausea freedom two-hours following patch activation .Twice as many patients treated with ZECUITY achieve freedom from headache pain compared to placebo .53% of patients treated with ZECUITY achieved relief from headache pain compared with 29% for placebo .84% of patients treated
Slide 13: Clinical Data – Zecuity and Imitrex Tablets
13 Clinical Data – Zecuity and Imitrex® Tablets 57% 68% 65% 20% 40% 60% 80% 100% Placebo Tab Imitrex® 50mg Imitrex® 100mg * * * * ns ns Imitrex® % Patients w/ Headache Pain Relief ZECUITY % Patients w/ Headache Pain Relief Zecuity % Patients w/ Nausea Freedom Imitrex® % Patients w/ Nausea Freedom 29
Slide 14: ZECUITY Associated with Substantially Less Treatment Emergent Nausea
14 •TEN is defined as the development of MRN after initiation of treatment •Up to 20% of patients receiving oral triptans experience TEN1 •In ZECUITY pivotal Phase 3, at two hours post- treatment2: .5% of ZECUITY patients had TEN* .14% of placebo patients had TEN* ZECUITY Associated with Substantial
Slide 15: Pivotal Phase Data Adverse Event Profile
15 Pivotal Phase 3 Data Adverse Event Profile •Application site events were typical of patches .Majority were mild in intensity and transient •Most patients experience some skin redness (typically goes away in 24hrs) •Low incidence of adverse events known as triptan sensations •Compared with product
Slide 16: Two 12-Month Open-Label Trials Confirm Safety of ZECUITY
16 Two 12-Month Open-Label Trials Confirm Safety of ZECUITY (n=662 patients) •Consistent relief of pain and nausea over 12 months •Very low incidence of triptan sensations (0.9%) •No increased skin irritation with repeat or increased use •Low incidence of allergic contact dermatitis (4%) •12-month c
Slide 17: ZECUITY Delivers Consistent Relief of Pain and Nausea Over 12 Months
17 0% 20% 40% 60% 80% 100% 1 2 3 4 5 6 7 8 9 10 11 12 % of Patients Treatment Month Headache Pain Relief at 2 Hours Nausea Free at 2 Hours ZECUITY Delivers Consistent Relief of Pain and Nausea Over 12 Months
Slide 18: ZECUITY Marketing Strategy
18 •Target physicians who treat higher % of MRN .~6,000 headache specialists prescribe 33+ million triptan units annually .Additional ~34,000 physicians prescribe 50+ million triptan units annually •Relentlessly deliver differentiating messages in label .Relief of both headache pain and MRN .Low rat
Slide 19: Powerful Marketing Messages Supported by the ZECUITY Label
19 Powerful Marketing Messages Supported by the ZECUITY Label Relief of BOTH Headache Pain and Nausea Low Incidence of Triptan Sensations Key Message for ZECUITY Approved ZECUITY Label Freedom from Headache Pain (1st and ONLY triptan to have headache pain free as a primary endpoint) SECTION 14: CLIN
Slide 20: Extensive ZECUITY Market Research Conducted in Preparation for Launch
20 Extensive ZECUITY Market Research Conducted in Preparation for Launch Physicians (n=770) •Message Testing •MD Segmentation •Product Positioning •Quantitative MD Concept Testing •Qualitative Concept Testing Patients (n=839) •Attribute Testing •Patient Segmentation •Commercial Packaging & Patient I
Slide 21: Pricing and Reimbursement Aligned with Product Positioning
21 •Insurance is >90% commercial private pay •Payors see value in ZECUITY for migraine .Recognize cost of poorly controlled migraine patients .Acknowledge GI issues as a problem •Broad formulary access expected .Tier 3 with a single step edit – parity to other brands •Aligned with product positionin
Slide 22: Quantitative Research Confirms the Market Opportunity for ZECUITY
22 •Physicians rated ZECUITY superior to oral, nasal, and injectable triptans for MRN patients on key attributes including: .Ability to use early in a migraine attack despite GI issues .Frequency of triptan sensations and overall tolerability .Elimination of nausea at 1 and at 2 hours •77% of MRN pa
Slide 23: Physicians Indicate Strong Preference for ZECUITY Over Orals for MRN Patients
23 Physicians Indicate Strong Preference for ZECUITY Over Orals for MRN Patients Ability to use early in attack despite GI issues Frequency of triptan related AEs Overall tolerability Nausea free at 2 hours Nausea free at 1 hour Effective in one dose Pain relief at 2 hours Speed of onset Pain relief
Slide 24: Physicians Indicate ZECUITY Preferable to Nasal Triptans
24 Physicians Indicate ZECUITY Preferable to Nasal Triptans Ability to use early in attack despite GI issues Frequency of triptan related AEs Overall tolerability Nausea free at 2 hours Nausea free at 1 hour Effective in one dose Pain relief at 2 hours Speed of onset Pain relief at 1 hour Ease of us
Slide 25: Physicians Rate ZECUITY Superior to Injectable Triptans
25 Physicians Rate ZECUITY Tolerability and Ease of Use Superior to Injectable Triptans Ability to use early in attack despite GI issues Frequency of triptan related AEs Overall tolerability Nausea free at 2 hours Nausea free at 1 hour Effective in one dose Pain relief at 2 hours Speed of onset Pain
Slide 26: Current Oral Triptan Users Expected to Be Significant Source of Patients
26 82% 9% 9% Expected Source of Zecuity Patients From Existing Triptan Users Oral Nasal Injection Current Oral Triptan Users Expected to Be Significant Source of ZECUITY Patients Patient’s Current Triptan Formulation Oral Nasal Injection Triptan Market: Share of Patients1 85.9% 6.7% 7.4% Top Box- “V
Slide 27: ZECUITY Brand Positioning is Distinct, Meaningful, Sustainable
27 ZECUITY Brand Positioning is Distinct, Meaningful, Sustainable ZECUITY will become the acute migraine treatment of choice for patients who suffer from migraine related nausea. . Game-changing, disruptive technology that bypasses GI tract . Addresses both headache pain and migraine-related nausea
Slide 28: Illustrative Market Segment Opportunity
28 •~8 million patients experience MRN in a majority of attacks •Treat 24 migraines per year •ZECUITY WAC pricing of $100 or $150/patch Illustrative Market Segment Opportunity $96 $192 $288 $384 $480 $144 $288 $432 $576 $720 $0 $100 $200 $300 $400 $500 $600 $700 $800 0.5% 1.0% 1.5% 2.0% 2.5% (millio
Slide 29: ZECUITY Patent Protection
29 ZECUITY Patent Protection •Issued patents provide protection into 2029 with pending applications into 2032 •Five issued US Patents (Orange Book listed) .Transdermal Methods and Systems for the Delivery of Anti-Migraine Compounds (April 2027) .U.S. 7,973,058 .U.S. 8,470,853 .Polyamine formulation
Slide 30: ZECUITY - First and Only Approved Migraine Patch
30 •Game-changing disruptive technology for migraine .Delivers sumatriptan, the #1 prescribed migraine medication .Five Orange-Book listed patents provide protection to April 2029 •Uniquely positioned to address migraine headache pain and MRN .Rapid relief of both headache pain and MRN with a low ra
Slide 31: References
31 References Slide 4 1.Lipton, R. Frequency and Burden of Headache-Related Nausea: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2013; 53(1):93-103. 2.Lipton, R. Healthcare Resource Utilization and Direct Costs Associated with Frequent Nausea in Episodic Migrai
Slide 32: References
32 References Slide 9 1.National Headache Foundation Patient Survey (June 2008). 2.Silberstein, S. Migraine Symptoms: Results of a Survey of Self-reported Migraineurs. Headache 1995;35:387-396. 3.NuPathe market research (2008, 2011). 4.Dodick, D. Triptan Nonresponder Studies: Implications for Clinic